Northland Capital Partners View on the City - Techfinancials (LON:TECH), Collagen Solutions (LON:COS)




Update regarding the Company’s two non-core subsidiaries




§  TechFinancials announces an update on its non-core subsidiaries B.O. TradeFinancials Limited ("BOT") and MarketFinancials Limited ("MF").

§  The Company had already confirmed the termination of the proposed sale of its shareholding in BOT and MF, following the decreasing levels of BOT activity during 2017 which negatively impacted overall revenue generated for the Company.

§  TechFinancials is now focusing its attention on supporting the most profitable parts of the business and developing new products and technologies, in particular its rapidly-growing blockchain-based products. The Company's wider strategy is to cease any B2C operation in the EU and to focus only on B2C trading in Asia Pacific region via its Joint Venture, DragonFinancials.  

§  Having re-considered its options with regard to its shareholdings in BOT and MF, the Board now confirms that BOT is in the process of notifying customers of its intention to terminate all of its activities related to operating its brand, OptionFair, and subsequently, to return all client funds. As a result of the notification, MF has terminated its market maker services with BOT, which was its only source of income. TechFinancials plans to sell MF, along with its license, and intends to provide a further update on this process in due course.



TechFinancials is a leading technology provider to binary options brokers.




Company to present at two US conferences in March 2018




§  Collagen Solutions will be presenting at two medical conferences in New Orleans between 6-9 March 2018.

§  The Company will exhibit at the American Academy of Orthopeadic Surgeons (AAOS) Annual Conference, the leading orthopaedic medical meeting. Jamal Rushdy, CEO, will also present at the accompanying Canaccord Genuity Musculoskeletal Conference.

§  The Company will present data from the recently announced successful eight-year clinical study of patients who received the Group’s ChondroMimetic® Cartilage Repair Scaffold for the repair of knee cartilage defects. They will also provide demonstrations of prototypes for their Bone Graft Substitute, ChondroMimetic® Cartilage Repair Scaffold, and Fibrillar Collagen development programmes.

§  Presenting at these conferences gives the Company significant outreach to a wide range of medical key opinion leaders, investors and manufacturers within the orthopeadic healthcare space.



Collagen Solutions develops, manufactures and supplies medical grade collagen biomaterials for use in research, medical devices, and regenerative medicine.


Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Collagen Solutions PLC named herein, including the promotion by the Company of Collagen Solutions PLC in any Content on the Site, the Company...



Archer Materials begins next phase in the development of their 12CQ Chip

Archer Materials (ASX: AXE) Chief Executive Officer Dr Mohammad Choucair shared the news with Steve Darling from Proactive that company has entered the next and very exciting phase of their development of the 12CQ Chip for Quantum Computing. Choucair telling Proactive what this next...

4 hours, 25 minutes ago

4 min read